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Precise temporal control of gene expression or
deletion is critical for elucidating gene function in
biological systems. However, the establishment of
human pluripotent stem cell (hPSC) lines with induc-
ible gene knockout (iKO) remains challenging. We
explored building iKO hPSC lines by combining
CRISPR/Cas9-mediated genome editing with the
Flp/FRT and Cre/LoxP system. We found that ‘‘dual-
sgRNA targeting’’ is essential for biallelic knockin of
FRT sequences to flank the exon. We further devel-
oped a strategy to simultaneously insert an activity-
controllable recombinase-expressing cassette and
remove the drug-resistance gene, thus speeding up
the generation of iKO hPSC lines. This two-step strat-
egywasused to establish human embryonic stemcell
(hESC) and induced pluripotent stem cell (iPSC) lines
with iKOofSOX2,PAX6,OTX2, andAGO2, genes that
exhibit diverse structural layout and temporal expres-
sion patterns. The availability of iKO hPSC lines will
substantially transform the way we examine gene
function in human cells.
INTRODUCTION
Human pluripotent stem cells (hPSCs), including embryonic
stem cells (ESCs) and induced pluripotent stem cells (iPSCs),
are useful tools for elucidating regulatory processes during early
development and disease pathogenesis under the human
genetic background (Takahashi et al., 2007; Thomson et al.,
1998; Yu et al., 2007). Genetic modification, including gene
knockout (KO), further expands the utility of hPSCs in studying
gene function in human embryogenesis or human genetic dis-
eases (Zou et al., 2010). However, constitutive KO of genes
that function in hPSC self-renewal or survival may render the
cells unable to propagate or survive, thus limiting their utility.
Furthermore, phenotypes arising from gene KO in early develop-
ment may obscure the analysis of gene function at later stages,
as many genes exert pleiotropic functions throughout differenti-Cation. Compensatory effects from other genes, unwanted line-
age selection, and cellular transformation are also potential
concerns of long-term culture of constitutive gene KO hPSCs.
Thus, precise temporal control of gene KO in hPSCs is often
necessary or highly beneficial for elucidating gene functions
and molecular pathways that underlie complex human traits.
In animals, inducible gene KO is typically accomplished by
combining homologous recombination-mediated gene targeting
with the flippase (Flp)/flippase recognition target (FRT) and the
Cre/LoxP system (Branda and Dymecki, 2004; Capecchi,
2005). However, generating inducible gene knockout (iKO)
hPSCs using the same procedure has proven very difficult and
laborious due to their much lower efficiency of homologous
recombination (Giudice and Trounson, 2008; Hockemeyer and
Jaenisch, 2010; Mali and Cheng, 2012; Zwaka and Thomson,
2003). Additionally, while homozygous targeted mice can be
generated through mating, the generation of homozygously tar-
geted hPSCs requires sequential targeting of the two individual
alleles (Bu et al., 2010; Song et al., 2010). Furthermore, repeated
gene targeting and cellular cloning is not only laborious, it may
also be detrimental to the maintenance and differentiation of
hPSCs (Baker et al., 2007). Thus, generation of iKO hPSC lines
is very challenging and requires new strategies to support the
next wave of discovery in human biology.
Several gene targeting strategies based on sequence-specific
nucleases (SSNs) have recently been developed to generate
double-strand breaks in targeted DNA, including zinc-finger nu-
cleases (ZFNs) (Miller et al., 2007; Porteus and Baltimore, 2003;
Urnov et al., 2010; Wood et al., 2011), transcription activator-like
effector nucleases (TALENs) (Boch et al., 2009; Christian et al.,
2010; Miller et al., 2011; Moscou and Bogdanove, 2009; Wood
et al., 2011), and the clustered regularly interspaced short palin-
dromic repeats (CRISPR)/CRISPR-associated (Cas) system
(Cong et al., 2013; Garneau et al., 2010; Gasiunas et al., 2012; Ji-
nek et al., 2012, 2013; Mali et al., 2013b; Sapranauskas et al.,
2011). These targeted double-strand breaks are then repaired
by either error-prone nonhomologous end-joining (NHEJ) or
high-fidelity homology-directed repair (HDR) (Helleday et al.,
2007; Lieber, 2010). Newly developed site-specific nucleases
have facilitated gene targeting in hPSCs including the generation
of gene KO hPSCs (Ding et al., 2013a, 2013b; Hockemeyer et al.,
2009, 2011; Mali et al., 2013b; Zou et al., 2009). However, an effi-
cient method to generate iKO hPSC lines has not been shownell Stem Cell 17, 233–244, August 6, 2015 ª2015 Elsevier Inc. 233
until recently (Gonza´lez et al., 2014). Gonzalez et al. created a
master hPSC line with a doxycycline (DOX)-inducible Cas9
expression cassette inserted in the AAVS1 site. After DOX treat-
ment and two rounds of single guide RNA (sgRNA) transfection
at specific times, random indels are introduced into targeted
gene sites via NHEJ, and potentially results in gene KO. How-
ever, the resultant cells are a mixed population of KO and non-
KO cells with unpredictable genotypes ascribed to the random
indel insertion. So, while the use of this iCRISPR system is a
potentially new way to generate a wide array of constitutive KO
hPSC lines after subcloning, the inefficiency of KO and random-
ness of indel insertionmake it less practical for inducing gene KO
in most of the cells during stem cell differentiation or at a partic-
ular stage of the pathological process. Thus, it is highly desirable
to establish an efficient iKO system so that target genes can be
deleted in a uniform manner at any given time.
Here, we report an efficient two-step strategy to generate iKO
hPSC lines by combining CRISPR/Cas9-mediated genome
editing with the Flp/FRT and Cre/LoxP system. We found that
‘‘dual-sgRNA targeting’’ is critical for biallelic knockin of FRT
sequences to flank the exon within a gene of interest in one
step. In addition, we devised a strategy to simultaneously insert
an activity-controllable recombinase-expressing cassette and
remove a drug-resistance gene, thus speeding up the generation
of iKO hPSC lines. This two-step strategy was reproducible as
demonstrated in the generation of hESC and iPSC lines with
iKO in SOX2, PAX6, OTX2, and AGO2 genes.
RESULTS
Generation of Homozygous FRT Knockin hPSC Lines by
Dual-sgRNA Targeting
The most critical step in engineering iKO hPSC lines is to
ensure predictable gene KO by knockin of FRT to flank an
exon via CRISPR/Cas9-catalyzed HDR. We developed a one-
step genome targeting method using CRISPR/Cas9 to generate
homozygous hPSC lines with a FRT-flanked exon within a gene
of interest instead of the conventional sequential targeting
strategy (Figure 1A). We then devised a unique method for
establishing iKO hPSC lines by simultaneous insertion of the
activity-controllable enhanced-flippase (Flpe) recombinase
expression cassette, named Flpe-ERT2, into the AAVS1 locus
and removal of the drug-resistance expression cassette in tar-
geted cells (Figure 1A). We reproduced this strategy using four
genes that contain either multiple exons (PAX6, OTX2, and
AGO2) or large exons (SOX2) as well as those that are not ex-
pressed (PAX6) or expressed at the pluripotent stem cell (PSC)
stage (SOX2, OTX2, and AGO2).
We first screened sgRNAs that effectively cleave DNA for
individual genes. For PAX6, a transcription factor expressed in
differentiated neural cells, but not in hPSCs (Zhang et al.,
2010), we designed seven sgRNAs that target unique sequences
in the introns flanking exon 4 (Figure S1A). Genomic deletion
assay in HEK293T cells indicated that sgRNA2 and sgRNA7 ex-
hibited the most effective genome deletion activity as revealed
by shortened PCR products (Figure S1B). We then introduced
two FRT sequences into the targeting sites by transfecting
hESCs with donor plasmids and the Cas9 plasmid, along
with sgRNA2, sgRNA7, or both sgRNA2 and sgRNA7 (Figure 1B).234 Cell Stem Cell 17, 233–244, August 6, 2015 ª2015 Elsevier Inc.After drug selection, PCR genotyping and sequencing showed
that 50% of the clones were targeted in one (heterozygous)
or both (homozygous) alleles in groups using sgRNA7 or both
sgRNA2 and sgRNA7 (Figure 1C and Table 1). In the group using
sgRNA2 alone, the targeting efficiency was extremely low (2 out
of 136 analyzed clones), and there were no homozygous clones
(Figure 1C and Table 1). Sequencing results from homozygous
clones revealed that the FRT sequence, which was expected
to be inserted into the sgRNA7 targeting site and was close to
the floxed drug-resistance gene (30 FRT site), was correctly in-
serted into both alleles of targeted cells using sgRNA7 or both
sgRNA2 and sgRNA7 (Figure 1D, Table 1, and Table S1). Surpris-
ingly, the 50 FRT site, which was expected to be inserted into the
sgRNA2 targeting site and was far away from the drug-resis-
tance gene expression cassette, was lost in both alleles of all
the homozygous clones from the group using only sgRNA7 (Fig-
ure 1D, Table 1, and Table S1). In contrast, the 50 FRT site was
correctly inserted in both alleles of PAX6 in most of the clones
from the group using both sgRNA2 and sgRNA7 (Figure 1D, Ta-
ble 1, and Table S1). Similar sequencing results were obtained
from heterozygous clones (Table S1). These results suggest
that using two sgRNAs to target the 50 and 30 FRT insertion sites
is necessary for generating correctly targeted homozygous
hESC lines. By using two sgRNAs to target the 50 and 30 FRT
insertion sites in the OTX2 locus, we generated homozygous
hESC lines with exon3 of OTX2 flanked by FRT sequences (Fig-
ure 1E, Table 1, and Figures S1C–S1E).
We then asked if targeting two sites is necessary for genes
with different structures and expression patterns. For this, we
designed sgRNAs targeting unique sequences flanking the
SOX2 gene. In contrast to PAX6, SOX2 is actively expressed
in hESCs (Rizzino, 2013) and the distance between designated
FRT insertion sites is approximately 3.5 kilobases (kb). By
screening sgRNAs, we identified sgRNA1A and sgRNA6B to
be effective in targeting 50 and 30 FRT insertion sites in the
SOX2 locus (Figures S2A–S2C). Similar to the results from
PAX6 targeting, the correctly targeted homozygous SOX2
clones were obtained only when using both sgRNA1A and
sgRNA6B. The use of either sgRNA alone resulted in either low
targeting efficiency and no identified homozygous clones (using
50 FRT insertion site targeting sgRNA, sgRNA1A) or loss of the 50
FRT site (using 30 FRT insertion site targeting sgRNA, sgRNA6B)
(Figures S2D–S2F, Table 1, and Table S1). Together, our results
indicate that utilizing sgRNAs targeting both 50 and 30 FRT inser-
tion sites is essential to generate correct homozygous hESC
lines with FRT-flanked exons. This strategy, named dual-sgRNA
targeting, is applicable to genes of varied structures.
Recently, the paired nickase strategy, which combines the
D10A mutant nickase version of Cas9 (Cas9 nickase) with a
pair of offset sgRNAs complementary to opposite strands of
the target site, has been developed to reduce the off-target
effect of Cas9-mediated genome editing since binding of both
offset sgRNAs is required for double-strand cleavage (Cho
et al., 2014; Mali et al., 2013a; Ran et al., 2013). We thus tested
the feasibility of generating homozygous FRT knockin hESC lines
by Cas9 nickase and the dual-sgRNA targeting strategy using
AGO2 and SOX2 as examples. sgRNApair 7, sgRNApair 14,
and sgRNApair 15 were identified to be effective in targeting
the 50 and 30 FRT insertion sites in AGO2 locus (Figures 2A,
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Figure 1. Generation of FRT Knockin hPSC Lines using Cas9 Nuclease
(A) Schematic diagram of the two-step strategy for generating an iKO hPSC line using PAX6 as an example. The first step is to generate an hPSC line with exons in
both alleles flanked by FRT sites using our dual-sgRNA targeting strategy. The second step is to remove the drug-resistance cassette and insert the Flpe-ERT2
expression cassette into the AAVS1 locus to establish the iKO hPSC line. Upon treatment with 4-OHT, Flpe-ERT2 will translocate into the nucleus and recombine
the FRT-flanked exons, thus resulting in frame-shift of a protein-coding sequence and KO of the targeted gene. Exons are shown as green or orange boxes, blue
triangles represent LoxP sites, and yellow triangles represent FRT sites.
(B) Schematic depiction of the targeting strategy for exon 4 of the PAX6 locus. Vertical arrows indicate sgRNA2 and sgRNA7 targeting sites. Red and blue
horizontal arrows indicate PCR genotyping primers for assaying PAX6 locus targeting and homozygosity, respectively. Donor plasmids: PGK, phosphoglycerate
kinase promoter; Puro, puromycin-resistance gene.
(C) PCR genotyping of hESC clones targeted by sgRNA2 (first panel), sgRNA7 (second panel), or both sgRNA2 and sgRNA7 (third panel). The expected PCR
product for the correctly targeted PAX6 locus is1,800 bp (red arrows). Correctly targeted clones underwent a further homozygosity assay (fourth panel). Clones
with the PCR products of 700 bp are heterozygous (blue arrow), and those clones without PCR products are homozygous (red asterisk).
(D) Representative sequencing results of targeted heterozygous or homozygous clones in the PAX6 locus using sgRNA2 (heterozygous), sgRNA7 (homozygous),
or both sgRNA2 and sgRNA7 (homozygous). The PAM sequences and FRT sequences are labeled in red and yellow, respectively.
(E) OTX2 locus targeting. PCR genotyping of hESC clones targeted by both sgRNA3 and sgRNA5 (left panel) or both sgRNA2 and sgRNA9 (middle panel) is
displayed. The expected PCR products for correctly targeted OTX2 locus are 1,200 bp (red arrows). Correctly targeted clones underwent a further homozy-
gosity assay (right panel). Those clones with the PCR products of 750 bp are heterozygous (blue arrow), and those clones without these PCR products are
homozygous (red asterisks).
See also Figures S1 and S2.
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Table 1. Summary of Targeting Experiments using CRISPR/Cas9
cell
line
targeted
gene targeting sgRNAs Cas9
clone
number
Targeted Clones Identified by PCR Genotyping
Homozygous Clones
Identified by Sequencing
heterozyous homozygous
targeting
efficiency (%)
homozyous
efficiency (%)
correct/
sequenced
homozygous
efficiency (%)
H9 PAX6 sgRNA2 WT 136 2 0 15 0 0/0 0.0
sgRNA7 WT 35 7 10 48.6 28.6 0/10 0.0
sgRNA2+sgRNA7 WT 34 10 8 52.9 23.5 8/8 23.5
H9 SOX2 sgRNA1A WT 66 1 0 1.5 0 0/0 0.0
sgRNA6B WT 71 37 6 60.6 8.5 0/6 0.0
sgRNA1A+sgRNA6B WT 84 27 11 45.2 13.1 10/11 11.9
sgRNApair1A+
sgRNApair6B
nickase 72 27 13 55.6 18.1 7/12 10.5
sgRNApair2A+
sgRNApair5B
nickase 87 45 14 67.8 16.1 11/14 12.6
H9 OTX2 sgRNA2+sgRNA9 WT 110 9 6 13.6 5.5 4/5 4.4
sgRNA3+sgRNA5 WT 56 31 3 60.7 5.4 1/2 2.7
H9 AGO2 sgRNApair7+
sgRNApair15
nickase 95 34 19 55.8 20 14/18 15.6
sgRNApair7+
sgRNApair14
nickase 81 20 14 42 17.3 14/14 17.3
D90A AGO2 sgRNApair7+
sgRNApair14
nickase 104 37 16 51.0 15.4 12/15 12.3
D90D SOX2 sgRNA1A+sgRNA6B WT 114 41 64 92.1 56.1 23/25 51.6
See also Table S1 and Table S2.S3A, and S3B). Using Cas9 nickase combined with sgRNApair 7
and sgRNApair 14, or sgRNApair 7 and sgRNApair 15, we gener-
ated homozygous hESC lines with exon3 of AGO2 flanked by
FRT sequences with an efficiency comparable to WT Cas9 (Fig-
ures 2A and 2B, Table 1). Similarly, by using Cas9 nickase and
two pairs of offset sgRNAs (sgRNApair 2A and sgRNApair 5B,
and sgRNApair 1A and sgRNApair 6B) to target the 50 and 30
FRT insertion sites in SOX2 locus, we generated homozygous
hESC lines with the SOX2 gene flanked by FRT sequences (Fig-
ures 2C–2E, Table 1).
Given the increasing use of iPSCs, we examined the homozy-
gous FRT knockin efficiency in SOX2 locus or AGO2 locus using
two human iPSC lines (Chen et al., 2014). The targeting efficiency
and homozygous efficiency in these human iPSCswas compara-
ble to those in hESCs. Both wild-type Cas9 and Cas9 nickase
worked well for genome targeting in human iPSCs (Figures S3C
and S3D and Table 1). Thus, our dual-sgRNA targeting strategy
canalsobeapplied togenerating homozygoushuman iPSC lines.
Establishing iKO hPSC Lines by Simultaneous Insertion
of an Inducible Cassette and Removal of a
Drug-Resistance Expression Cassette
To generate iKO hPSC lines, we needed to remove the drug-
resistance expression cassette in the FRT-flanked gene locus
and insert the control element, Flpe-ERT2, into the AAVS1 locus.
This is typically achieved by sequential removal of the drug-
resistance cassette through Cre recombinase application, geno-
typing of resulting clones, and expansion of corrected clones,
and then a second round of targeting occurs to insert the control
element. This laborious process takes approximately 6 weeks.236 Cell Stem Cell 17, 233–244, August 6, 2015 ª2015 Elsevier Inc.Considering the high genome-targeting efficiency of the
CRISPR/Cas9 system, we explored the one-step strategy to
simultaneously remove the drug-resistance gene expression
cassette and target the Flpe-ERT2 expression cassette into the
AAVS1 locus. hESCs with the exon 4 of PAX6 flanked by FRT
sequences were electroporated with a donor plasmid containing
Flpe-ERT2 expression cassette (AAVS1-neo-CAG-FlpeERT2),
sgRNA T2 targeting AAVS1 locus, and Cas9-2A-Cre plasmid
that enabled co-expression of Cas9 and Cre recombinase in
the same cells (Figure 3A). After drug selection, 14 out of 40
clones were identified to be correct with insertion of the
Flpe-ERT2 expression cassette in the AAVS1 locus and removal
of the PGK-puromycin cassette in both alleles of the PAX6 locus
(Figures 3B–3D). Using the same strategy, we inserted the CAG-
Flpe-ERT2 cassette into the AAVS1 locus and removed the PGK-
puromycin cassette in hESCs with exon 3 of OTX2 flanked by
FRT sequences at the same time. Four out of sixteen clones
were identified as correct (Figures 3B–3D). SOX2 iKO and
AGO2 iKO hESC lines as well as SOX2 iKO hiPSC lines were es-
tablished using a similar strategy with comparable efficiency
(Figures S4A–S4C). Thus, this one-step approach enables
establishment of iKO human ESC or iPSC lines within 4 weeks.
Off-target effects areamajor concernof theCRISPR/Cas9sys-
tem. By genomic PCR and Sanger sequencing, we sequenced
six to seven potential off-targets for every sgRNA target site in
the above iKO hESC lines according to online tools (http://
crispr.mit.edu/). In the total 114 potential off-target sites, we did
not detect any indel formation (TableS2), suggesting a high spec-
ificity of CRISPR/Cas9-based genome targeting in generating
gene iKO hPSC lines.
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Figure 2. Generation of FRT Knockin hPSC Lines using Cas9 Nickase
(A) Schematic depiction of the targeting strategy for exon 3 of the AGO2 locus. Vertical arrows indicate targeting sites for sgRNApair 7 (sgRNA7+sgRNA9),
sgRNApair 14 (sgRNA14+sgRNA17), or sgRNApair 15 (sgRNA15+sgRNA18). PCR genotyping primers for the AGO2 locus targeting test (red arrows) or
homozygosity test (blue arrows) are indicated.
(B) PCR genotyping of hESC clones targeted by both sgRNApair 7 and sgRNApair 15 (left panel) or both sgRNApair 7 and sgRNApair 14 (middle panel). Expected
PCR products for the correctly targeted AGO2 locus are1,400 bp (red arrows). Correctly targeted clones underwent a further homozygosity assay (right panel).
Those clones with the PCR products of about 420 bp are heterozygous (blue arrow), and those without these PCR products are homozygous (red asterisk).
(C) Schematic diagram depicting the targeting strategy for theSOX2 locus using Cas9 nickase. The vertical arrows indicate targeting sites bySOX2 sgRNApair 1A
(sgRNA1A+sgRNA1B), sgRNApair 2A (sgRNA2A+sgRNA2B), sgRNApair 5B (sgRNA5A+sgRNA5B), or sgRNApair 6B (sgRNA6A+sgRNA6B). PCR genotyping
primers for the SOX2 locus targeting test (red horizontal arrows) or homozygosity test (blue horizontal arrow) are indicated.
(D and E) SOX2 locus targeting. PCR genotyping of hESC clones targeted using Cas9 nickase combined with either sgRNApair 2A and sgRNApair 5B (D) or
sgRNApair 1A and sgRNApair 6B (E) is displayed. Expected PCR products for the correctly targeted SOX2 locus are1,700 bp (red arrow). Those clones with the
PCR products of about 550 bp are heterozygous (blue arrow), and those clones without these PCR products are homozygous (red asterisks).
See also Figure S3.Expression of Target Genes Is Depleted upon Induction
To validate inducible gene KO in our established hPSCs, we
treated the cells with 4-hydroxytamoxifen (4-OHT) and assayed
iKOefficiency at the genomic level.Weused external primer pairs
to detect both the un-recombined FRT-flanked exons and re-Ccombined FRT-flanked exons after 4-OHT treatment. Addition-
ally, we used an internal primer pair as a more sensitive measure
to detect the un-recombined FRT-flanked exons (Figure 4A). As
shown in Figures 4B–4D, 4-OHT treatment depleted the FRT-
flanked exon in the OTX2 locus in a time- and dose-dependentell Stem Cell 17, 233–244, August 6, 2015 ª2015 Elsevier Inc. 237
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Figure 3. Generation of iKO hPSC Lines
(A) Schematic depiction of the targeting strategy
for the AAVS1 locus. Exons are shown as orange
boxes. The vertical arrows indicate the targeting
site by sgRNA T2 in the AAVS1 locus. The orange
horizontal arrows indicate PCR genotyping
primers for AAVS1 locus targeting. Donor plas-
mids: SA-Neo, splice acceptor sequence followed
by a T2A self-cleaving peptide sequence and the
neomycin resistance gene; CAG, synthetic
CAGGS promoter containing the actin enhancer
and the cytomegalovirus early promoter; Flpe,
enhanced Flp recombinase; ERT2, mutated ligand-
binding domain of estrogen receptor (ER).
(B) Genotyping strategy for Cre recombinase-
mediated removal of the resistance gene expres-
sion cassette in the FRT knockin PAX6 or OTX2
locus. Exons are shown as green boxes, blue tri-
angles represent LoxP sites, and yellow triangles
represent FRT sites. The green and black arrows
indicate PCR primers for assaying removal of the
Cre recombinase-mediated resistance gene
expression cassette and homozygosity, respec-
tively.
(C) PCR genotyping of PAX6- or OTX2-iKO hESCs
clones. The expected PCR products for the
correctly targeted AAVS1 locus are 1,000 bp
(orange arrows). The expected PCR products for
PGK-puromycin (PGK-Puro) removal in the
flanked PAX6 or OTX2 locus are 700 bp or
1,500 bp (green arrows), respectively. Those
clones with the positive PCR products of
1,800 bp (in FRT knockin PAX6 locus, black ar-
row) or 1,450 bp (in FRT knockin OTX2 locus,
black arrow) in the homozygosity test are hetero-
zygous, and those clones without these PCR
products are homozygous (PGK-Puro was
removed in both targeted alleles). Those clones with the positive PCR products in the homozygosity test are heterozygous. Vertical arrows indicate clones with
the correct AAVS1 locus targeting, PGK-Puro removal, and homozygosity of PGK-Puro removal in the FRT knockin PAX6 or OTX2 locus.
(D) Summary of the efficiency of second-step targeting in the hESC line with the exons of PAX6 or OTX2 flanked by FRT sequences.
See also Figure S4.manner. Most of the FRT-flanked exons were depleted within
48 hr of 4-OHT treatment (85.2% for internal primer pair, 97.8%
for external primer pair), and almost complete depletion of
flanked exons could be obtained after 96 hr of 4-OHT treatment
at a concentration of 2.5mM (Figure 4B, left panel, and Figure 4C).
Treatmentwith 4-OHTat a concentration as lowas0.83mMeffec-
tively depleted FRT-flanked exons (94.1% for internal primer pair,
100% for external primer pair) (Figure 4B, right panel, and Fig-
ure 4D). Depletion of the FRT-flanked genomewas also achieved
in differentiated neural cells from OTX2 iKO hESCs after 4-OHT
treatment (Figure 4E). These results suggest that 4-OHT treat-
ment can efficiently deplete the FRT-flanked genome at the
PSC stage or in differentiated cells. At the protein level, the
expression of OTX2 was similar between OTX2 iKO hPSCs and
WT hPSCs without 4-OHT treatment, demonstrating that our
genome editing process does not affect the normal expression
of the target gene (Figure 4F). OTX2 was significantly diminished
within 2–3 days of 4-OHT treatment at the PSC stage or during
neural differentiation (Figures 4F and 4G). Transient pretreatment
ofOTX2 iKOcellswith 4-OHTpermanently eliminated expression
of OTX2 protein during neural differentiation as revealed by
immunoblotting (Figure 4H) and immunofluorescence (Figure 4I).238 Cell Stem Cell 17, 233–244, August 6, 2015 ª2015 Elsevier Inc.Similarly, PAX6 iKO cells exhibit similar expression of PAX6 pro-
tein when compared withWT cells during neural differentiation in
the absence of 4-OHT. 4-OHT treatment effectively depleted the
FRT-flanked exon of PAX6 and PAX6 protein expression in PAX6
iKO cells (Figures S5A–S5E and Table S3).
Functional Consequence of Gene KO during
hPSC Differentiation
Inducible gene KO hPSCs offer a tool to look into the roles of
genes in human cells at different developmental stages. As a
proof of principle, we examined the roles of OTX2 during early
neural development. Animal studies indicate thatOTX2 is essen-
tial in defining the identities of brain regions, especially the fore-
brain and midbrain, during development (Acampora et al., 1995;
Matsuo et al., 1995). However, its roles in human neural develop-
ment are less well known.We found thatOTX2was expressed at
the PSC stage, but its expression increased substantially during
neural differentiation and plateaued at day 2 (Figure S5F). This
result suggests thatOTX2may play a role in early neuroepithelial
development as well as neural patterning. As shown in Figure 4J,
depletion of OTX2 before neural induction resulted in a severe
reduction in the expression of neuroepithelial markers such as
ZIC1 and PAX6. The expression of pan-forebrain marker
(FOXG1) and dorsal forebrain markers (EMX1 and LHX2) was
also dramatically decreased. This result suggests that OTX2 is
required for inducing anterior neuroectoderm and/or conferring
the forebrain character to hPSC-derived neuroectoderm pro-
genitors at an early stage.
We then asked what effect OTX2 KO will have after forebrain
neuroepithelial cells are differentiated. Treatment of differenti-
ating hPSCs with 4-OHT at day 8, a stage when the expression
of most of the forebrain neuroectoderm genes has reached a
plateau (Figure S5F), did not affect the expression of forebrain
transcription factors FOXG1 andZIC1 nor hindbrain transcription
factors EN1, HOXB2, HOXA2, and HOXA3 (Figures S5G and
S5H), but it significantly reduced the expression of dorsal fore-
brain genes such as PAX6, EMX1, and LHX2 at day 16 (Fig-
ure 4K). This result suggests that OTX2 is not required for the
maintenance of forebrain identity of the neuroepithelia, but it is
critically involved in the dorsal-ventral patterning of forebrain
neuroepithelia after forebrain neuroepithelial cells are differenti-
ated. Taken together, these results illustrate that our iKO hPSC
lines enable dissection of the temporally regulated functions of
genes under the human genetic background.
Generation of a Multiple-Gene iKO hPSC Line
Many gene products often interact with and/or compensate
each other, and it is sometimes necessary to conditionally delete
more than one gene in order to elucidate their functions. To
determine if our strategy is applicable for generating hPSC lines
with iKO ofmultiple genes, we tested the possibility of generating
homozygous hPSC lines with multiple genes flanked by applying
our dual-sgRNA targeting strategy. hESCs were electroporated
by plasmid encoding Cas9, the two donor plasmids for PAX6
or SOX2 with a distinct drug-resistance gene (neomycin for
PAX6 and puromycin for SOX2), and two pairs of sgRNAs for
PAX6 or SOX2 (Figure 5A). After hESCs underwent selection
with both neomycin and puromycin for 2 weeks, we found that
57 out of 86 clones were targeted in both the PAX6 and the
SOX2 locus, and among them, 22 clones were homozygous
(Figures 5B–5D). We randomly selected three homozygous
clones for sequencing. Two out of three clones were correctly
targeted with intact 50 FRT sites and 30 FRT sites in all four alleles
in PAX6 and SOX2 loci. We further established the PAX6/SOX2
iKO hPSC line by simultaneous removal of the drug-resistance
expression cassette in the FRT-flanked gene locus (puromycin
in SOX2 locus and neomycin in PAX6 locus) and insertion of
Flpe-ERT2 into the AAVS1 locus by electroporation with the
AAVS1-blasticidin-CAG-FlpeERT2 donor plasmid, sgRNA T2,
Cas9-2A-Cre, and pCAG-Cre plasmids and subsequent blas-
ticidin selection. 1 out of 24 clones (efficiency of 4.2%) was
identified as a correct clone. 4-OHT treatment depleted the
FRT-flanked exons in both PAX6 locus and SOX2 locus, demon-
strating the feasibility of multiple-gene iKO in human cells using
our iKO system (Figure S6).
DISCUSSION
We have established an efficient and effective strategy to
generate iKO hPSC lines. It takes advantage of the high biallelic
targeting efficiency of the CRISPR/Cas9 system for knockin ofCFRT sites, but more importantly, it relies on the dual-sgRNA-
mediated gene targeting method we have developed. This
strategy enables predictable KO of genes with different struc-
tural organization and/or expression patterns, including those
that are silent (PAX6) or actively expressed (SOX2, OTX2, and
AGO2) in the PSC stage, or those bearing a larger exon
(SOX2). Furthermore, we have developed a one-step method
to simultaneously remove the drug-resistance gene and insert
the Flpe-ERT2 cassette at the AAVS1 site, which overcomes
the laborious sequential targeting/cloning required by traditional
methods. Our two-step strategy enables production of iKO
hPSC lines, including hESC and human iPSC lines, in as little
as 12 weeks. This strategy can also be used to target multiple
genes at once without extending the time frame, thus enhancing
the utility of this method for the study of multifaceted processes.
The hPSC lines established in this way are easy to use and the
target genes can be deleted in a uniform manner at any given
time by the simple application of 4-OHT.
In this study, it is interesting to find that two individual sgRNAs
(or sgRNA pairs for nickase) targeting separate FRT insertion
sites are necessary to generate correct homozygous FRT
knockin hPSCs. Using a single sgRNA targeting the 50 FRT inser-
tion site (50 sgRNA) results in a very low targeting efficiency with
no homozygous clones. Using a single sgRNA targeting the 30
FRT insertion site, we obtained homozygously targeted clones,
but the 50 FRT sequence was lost. Only by using both 50 sgRNA
and 30 sgRNA (dual sgRNAs) can we obtain correct homozygous
FRT-knockin hPSC clones with FRT sequences inserted in both
the 50 and 30 FRT insertion sites (Figure 1, Table 1, and Table S1).
The reason behind the inefficient targeting by a single sgRNA is
not clear. One potential explanation is the incomplete HDR using
the donor plasmid as the template. After the Cas9/sgRNA medi-
ated double-strand break at the designated 30 FRT insertion site,
the cells may use the donor plasmid as a template to repair the
double-strand break, resulting in correct insertion of the FRT
sequence and drug-resistance gene in the 30 FRT insertion
site. At the 50 FRT insertion site, however, cells tend to use
cognate genomic DNA, instead of the donor plasmid, as a tem-
plate for repair, thus resulting in the loss of the FRT sequence.
Regardless of potential mechanisms, our findings demonstrate
that the dual-sgRNA targeting strategy is critical for generating
correct homozygous FRT knockin hPSCs. Technically, our opti-
mized transfection, drug selection, and culture condition for
selected individual cells, as detailed in the Experimental Proce-
dures, should make it feasible for other labs to generate FRT
knockin hPSC lines.
Off-target effects are a major concern with the CRISPR/Cas9
system. Our sequencing analysis of a total of 114 potential off-
target sites showed no indel formation in any of these sites (Table
S2), suggesting relatively specific genome targeting of the
CRISPR/Cas9 system in hPSCs. This is consistent with recent
studies using whole-genome sequencing analysis (Smith et al.,
2014; Veres et al., 2014) or capture sequencing (Mandal et al.,
2014). Thus, the CRISPR/Cas9 system is effective and specific
in generating gene iKO hPSC lines.
Generation of iKO hPSCs has been reported by Gonza´lez et al.
using their iCRISPR system (Gonza´lez et al., 2014). They first
created a common inducible line by integrating the Tet inducible
system in the AAVS1 site and then introducing sgRNA to target aell Stem Cell 17, 233–244, August 6, 2015 ª2015 Elsevier Inc. 239
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Figure 4. Inducible Depletion of OTX2 and Functional Consequences
(A) Schematic depiction of PCR primer sets for genotyping. Blue arrows: external primer pair; red arrows: internal primer pair.
(B–D) Depletion of FRT-flanked exons of OTX2 in a time-dependent (at 2.5 mM, left panel) and dose-dependent (at 72 hr, right panel) manner upon 4-OHT
treatment. The expected sizes of PCR products using external primer pairs for un-recombined FRT-flanked exons (blue arrow, upper) or recombined FRT-flanked
exons (blue arrow, lower) are 1,600 bp or 650 bp, respectively. The red arrow indicates the PCR products (650 bp) using internal primer pairs. The black
arrow indicates PCR products (420 bp) amplified from the AGO2 locus, which did not undergo recombination (control). The KO efficiency was plotted in (C) and
(D) by calculating the density of PCR products from three or four independent experiments. Data are represented as mean ± SEM.
(E) Depletion of FRT-flanked exons ofOTX2 upon 72 hr of treatment with 2.5 mM 4-OHT inOTX2 iKO neuroepithelial cells that underwent neural differentiation for
8 days. The arrows are indicated as in (B).
(F) Western blotting shows depletion of OTX2 protein upon treatment with 1.25 mM 4-OHT for 72 hr in OTX2 iKO and parental hESCs.
(G) Western blotting shows OTX2 protein expression along neural differentiation upon treatment with 1.25 mM 4-OHT at day 3.
(legend continued on next page)
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Figure 5. Flanking Exons of Multiple Genes in One Step
(A) Schematic overview depicting the strategy for simultaneously targeting both the PAX6 locus and theSOX2 locus. Donor plasmids: Pur, PGK-driven puromycin
resistance gene; Neo, PGK-driven neomycin resistance gene.
(B) PCR genotyping of hPSC clones targeted using the SOX2 donor plasmid (Puro), the PAX6 donor plasmid (Neo), WT Cas9, SOX2 targeting sgRNAs (sgRNA1A
and sgRNA6B), and PAX6 targeting sgRNAs (sgRNA2 and sgRNA7). Expected PCR products for the correctly targeted SOX2 locus or PAX6 locus are1,700 bp
or 1,800 bp (red arrows), respectively. The vertical arrows indicate clones with both the SOX2 locus and the PAX6 locus targeted.
(C) Correctly targeted clones in both the SOX2 locus and the PAX6 locus underwent further homozygosity testing in both the SOX2 locus and the PAX6 locus.
Those clones without the PCR products of 700 bp at the PAX6 locus (blue arrow, upper) and without the PCR products of 550 bp at SOX2 locus (blue arrow,
lower) are homozygous clones targeted in both the SOX2 locus and the PAX6 locus (vertical arrows).
(D) Summary of the targeting efficiency and homozygous efficiency in both the SOX2 locus and the PAX6 locus.
See also Figure S6.specific DNA site to induce KO. While the intention is reasonable
and it potentially allows the generation of versatile new constitu-
tive KO lines, its dependence on Cas9/sgRNA-mediated DNA
double-strand breaks and subsequent random indel formation
makes it nearly impossible for it to generate clonal iKO lines. In
order to induce KO in differentiated cells, cells need to be pre-
treated with DOX (to induce Cas9 expression) and then trans-
fected with sgRNA (to target a gene to induce gene KO) (Gonza´-
lez et al., 2014). Transfection without cloning is not likely to(H) Western blotting shows permanent depletion of OTX2 expression upon 4
differentiation.
(I) Immunostaining shows depletion of OTX2 protein expression at day 8 followin
differentiation. Scale bar, 20 mM.
(J and K) RT-qPCR shows gene expression after 4 days of treatment with 1.25 mM
8 days after neural differentiation (cells were collected at day 16; K). Student’s t t
See also Figure S5, Table S3, and Table S5.
Cachieve a uniform population, even with two rounds of transfec-
tion. That will result in a mixed cell population consisting of those
with and those without gene targeting. Even among the sgRNA-
targeted cells, cells will exhibit distinct genotypes from each
other after random indel formation in one or both alleles of a
target gene. Only those with the out-of-frame indel formation in
both alleles will exhibit gene KO. Therefore, the resultant cells
will always be a mixture and the proportion of KO cells depends
on the rate of out-of-frame indel formation. Indeed, the averagedays of treatment with 1.25 mM 4-OHT commenced 2 days before neural
g 4 days of treatment with 1.25 mM 4-OHT commenced 2 days before neural
4-OHT 2 days before neural differentiation (cells were collected at day 8; J) or
est. Data are represented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
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KO (out-of-frame) efficiency by iCRISPR is 64% from five individ-
ual genes (Table S3). The inefficient iKO also applies to themodi-
fied iCRISPR method, which simultaneously knocks in sgRNA
expression cassette together with Tet-on Cas9 to bypass the
sgRNA transfection step (Table S3).
In contrast, our iKO system is based on Flpe-recombinase-
mediated, high-efficiency excision of the DNA segment between
FRT sites, resulting in predictable exon loss and frame-shift,
which leads to geneKO in nearly all the cells.While it takes longer
to generate a line (10–12 weeks), gene KO can be induced at any
time by simply applying 4-OHT without cell manipulations (Table
S3). This is particularly important for dissecting gene function not
only in the stem cell stage but more importantly during stem cell
differentiation and/or pathological processes. For example, we
found that OTX2, a homeodomain protein that is critical for
defining the fore-midbrain boundary (as indicated by animal
studies; Acampora et al., 1995; Matsuo et al., 1995) may also
be essential for the generation of human forebrain progenitors
at an early stage and for maintaining the dorsal forebrain identity
of presumptive forebrain precursors at a later stage. The same
strategy may be used to delete a gene in functional cells that
are differentiated from patient iPSCs, thus dissecting its role in
a pathological process. It may also enable controlling the fate
of transplanted human cells in vivo. For example, after transplan-
tation, treatment with 4-OHT can deplete a cell-cycle gene to
prevent proliferation of transplanted cells, thus avoiding poten-
tial tumorigenesis. The ease of use and precise time resolution
for gene deletion of the iKO hPSCs established with our new
method will enable discovery of novel roles of known genes in
human biology and pathology.EXPERIMENTAL PROCEDURES
Construction of Donor Plasmids, sgRNAs, and Cas9 Plasmids
Human codon-optimized Streptococcus pyogenes wild-type Cas9 (Cas9-2A-
GFP) and Cas9 nickase (Cas9D10A-2A-GFP) were obtained from Addgene
(plasmid #44719 and plasmid #44720) (Ding et al., 2013b). Cas9-2A-Cre was
constructed by replacingGFP in theCas9-2A-GFPwith theCre cDNAamplified
frompCAG-Cre (Addgeneplasmid#13775) (MatsudaandCepko, 2007). sgRNA
T2wasobtained fromAddgene (plasmid#41818) (Mali et al., 2013b).To facilitate
the sgRNA construction, we generated Cas9 sgRNA vector. A previously
described chimeric guide RNA expression cassette was ordered as gBlocks
and cloned into the gRNA cloning vector (Addgene plasmid #41824) (Mali
et al., 2013b). The new sgRNA cloning vector (Cas9 sgRNA vector) includes
two BbsI restriction sites for rapid cloning of sgRNA (Table S4). Briefly, Cas9
sgRNA vector was digestedwith BbsI and gel purified. A pair of oligos including
targeting sequences was annealed and cloned into the BbsI-digested Cas9
sgRNA vector. The guide sequence of individual sgRNAs can be found in Table
S2. PL552 donor plasmid vector containing a floxed PGK-puromycin expres-
sion cassette was constructed by replacing the neomycin gene in the PL452
(Frederick National Lab) with a puromycin gene. To generate the donor plasmid
for FRT-knockin, DNA fragments of about 1–1.25 kb in length were PCR ampli-
fied from the genomic DNA beyond the designated 50 and 30 FRT insertion sites
of a targeted gene. The DNA fragment between the designated 50 and 30 FRT
insertion sites (containing the exon) was also amplified from genomic DNA.
FRT sequences were included in the PCR primers. These three fragments
were then cloned into the multiple cloning sites of plasmid PL552. For simulta-
neous targeting of PAX6 andSOX2, the PL452 PAX6 donor plasmidwas gener-
ated by inserting the DNA fragments into the PL452 vector containing a floxed
PGK-neomycin expression cassette. To generate AAVS1-neo-CAG-FlpeERT2
donor plasmid, we replaced the puromycin resistance gene in the AAVS1-pur-
CAG-hrGFP plasmid (Addgene plasmid #52344) (Qian et al., 2014) with the
neomycin resistance gene to obtain AAVS1-neo-CAG-hrGFP. We next ampli-242 Cell Stem Cell 17, 233–244, August 6, 2015 ª2015 Elsevier Inc.fied mammalian-codon-optimized Flpe recombinase cDNA and ERT2 cDNA
by PCR from pDIRE (Addgene plasmid #26745) (Osterwalder et al., 2010) and
pCAG-FlpeERT2 (Addgene plasmid #14756) (Matsuda and Cepko, 2007),
respectively. The mammalian codon-optimized Flpe fused with ERT2 was
inserted into the AAVS1-neo-CAG-hrGFP to replace GFP to get the AAVS1-
neo-CAG-FlpeERT2 donor plasmid. AAVS1-blasticidin-CAG-FlpeERT2 donor
plasmid was constructed by replacing the neomycin resistance gene in the
AAVS1-neo-CAG-FlpeERT2 donor plasmid with the blasticidin resistance gene.
Cell Culture
hESCs (line WA09 [WiCell], passages 20–40), D90A, and D90D (Chen et al.,
2014) were maintained on a feeder layer of irradiated embryonic mouse fibro-
blasts (MEFs) in hPSC medium consisting of DMEM/F12 (Life Technologies),
1X Non-Essential Amino Acids (Life Technologies), 0.5X GlutaMAX (Life
Technologies), and 0.1 mM b-mercaptoethanol (Sigma). 4 ng/ml FGF-2 (R&D
Systems) was added when feeding cells, as previously described (Zhang
et al., 2001). The D90A hiPSC line was generated from fibroblasts of an ALS
patient with the SOD1-D90A mutation by a Sendai virus. The D90D hiPSC
line was a genetically corrected line from D90A hiPSCs (Chen et al., 2014).
Electroporation
Electroporation was performed using the Gene Pulser Xcell System (Bio-Rad)
at 250 V, 500 mF in 0.4 cm cuvettes (Phenix Research Products). Details are
given in Supplemental Experimental Procedures.
Genomic Deletion Assay
Pairs of sgRNA plasmids with Cas9 plasmids were co-transfected into
HEK293T cells via calcium phosphate transfection. 72 hr later, 1 3 106 cells
were collected and genomic DNA was extracted. To detect the effective
genome deletion caused by a pair of sgRNAs, genomic PCR was performed
with a pair of primers flanking the deletion.
Off-Target Analysis of Established hPSC Lines
The potential off-target sites were selected according to online tools provided
by Feng Zhang’s laboratory (http://crispr.mit.edu/) (Hsu et al., 2013). These
sites were amplified by genomic PCR and then underwent Sanger sequencing.
Six or seven potential off-targets were sequenced for every sgRNA target site.
The information about the selected off-target sites is listed in Table S2.
Western Blotting, Immunocytochemistry, and qRT-PCR
These procedures were performed using standard methods. Details are given
in Supplemental Experimental Procedures. Primers used are listed in Table S5.
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